56 results about "S syndrome" patented technology

The invention relates to the technical field of biological medicines, and provides application of NR1D1 in treating sicca syndrome, related medicines and the like. The scheme of the invention discovers and proves that the NR1D1 gene participates in the sicca syndrome pathogenesis process, can significantly influence the function of submaxillary gland cells, and is an effective sicca syndrome immune inflammation regulation diagnosis and treatment target.

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

The application discloses a protein zwitterionic polymer conjugate and a preparation method and application thereof. A multifunctional new medical biomaterial with mucosal adhesion, wetting, lubrication and microbial adhesion prevention is designed and synthesized, so that a new breakthrough is brought to the clinical demand of solving Sjogren's syndrome. In addition, the application has wide application prospects in the fields of oral lubrication, ophthalmic lubrication, joint repair and the like.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses of the compound in drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome, wherein each substituent in the general formula (I) is as defined in the specification.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The invention discloses an application of cGAS as a target in prevention / treatment of Leigh syndrome. The method comprises the following steps: constructing NDufs4; a cGAS DKO gene knockout mouse model is researched, and the result shows that by knocking out cGAS, the glial hyperplasia phenomenon weakening of the mouse with the Like's syndrome can be improved, and neuroinflammation is inhibited. The invention provides a new potential drug target and a treatment strategy for treating the Like's syndrome, and lays a foundation for researching and developing a new drug for treating the Like's syndrome.

The invention discloses a system for screening Reiye's syndrome based on NOD2 gene new pathogenic mutation. The invention provides a computer device. The computer device comprises a memory, a processor and a computer program stored in the memory, the processor executes the computer program to implement the following steps: receiving NOD2 gene data (cDNA sequence) of a person to be tested; the method comprises the following steps: reacting the NOD2 gene with any one of the following mutations in SEQ ID No.2 stored in a computer: c.380Cgt; t, c, 2657Cgt; t, c.328Ggt; a, c.1295Cgt is selected from the group consisting of the T, c, 1981Ggt; c, and c, 2452Agt; c) performing comparison; and according to a comparison result, outputting information about whether the to-be-detected person is or is suspected to be a patient with the Reiderson's syndrome or about the risk of suffering from the Reiderson's syndrome. The novel pathogenic gene mutation form related to the NOD2 gene of the patient with the Reidersi syndrome is found, the novel pathogenic gene mutation form can serve as a target object to be used for developing a reagent and a computer device for diagnosing or screening the Reidersi syndrome, and the novel pathogenic gene mutation form has important significance on diagnosis and screening of the Reidersi syndrome.

The invention relates to a primary sicca syndrome biomarker. The biomarker is telomere relative length. By detecting the relative length of telomeres in peripheral blood leucocytes and combining a statistical model, the early diagnosis sensitivity and specificity of the primary sicca syndrome are remarkably improved. Compared with a traditional diagnosis method, the disease risk can be predicted before clinical symptoms appear, and therefore early intervention of diseases is achieved.

This invention provides a novel method for treating Sjögren's syndrome in individuals requiring treatment. [Solution] A method is provided for treating or preventing Sjögren's syndrome in a person in need, comprising administering a therapeutically effective amount of an anti-BAFFR antibody or a functional fragment thereof to the person. Preferably, the anti-BAFFR antibody or functional fragment thereof is ianarumab.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for Down's syndrome diagnosis. The invention particularly relates to application of a detection reagent for detecting the methylation level of a CpG site of a nucleic acid marker in preparation of a Down's syndrome diagnostic kit. The nucleic acid marker comprises a) an SIM2 gene segment as shown in SEQ ID NO: 1 or a polynucleotide segment complementary to the SIM2 gene segment, and / or b) a CRYBG1 gene segment as shown in SEQ ID NO: 2 or a polynucleotide segment complementary to the CRYBG1 gene segment.

Methods and compositions for the treatment of ACTH-dependent Cushing's syndrome are provided herein.

The application discloses a traditional Chinese medicine compound for treating Sjogren's syndrome and a preparation method and application thereof. The traditional Chinese medicine compound is prepared from Huangqi, Danshen, Maidong and Dendrobium officinale. The traditional Chinese medicine for treating Sjogren's syndrome has the functions of tonifying qi, generating fluid, nourishing yin, moistening dryness, promoting blood circulation and removing blood stasis. The traditional Chinese medicine for treating Sjogren's syndrome has unique advantages, can obviously improve the dry mouth, anti-fatigue, submandibular gland lymphocyte infiltration and T cell subpopulation proportion disorder of Sjogren's syndrome, and is an effective pure traditional Chinese medicine preparation.

The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R1, R2a, and R2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.

The present disclosure relates to methods for treating Sjogren's syndrome disease using compounds of formula (I) or pharmaceutically acceptable salts thereof. Also disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof for treating Sjogren's syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms and kits for use in the disclosed uses and methods.

The present application relates to compounds of formula (A), wherein R1 is selected from formula (II) and formula (III) and R2 is selected from formula (IV), formula (V) and formula (VI), as IRAK4 inhibitors for use in methods of treating, for example, asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases and autoinflammatory / autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present application are, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(imidazo[l,2-b]pyridazin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide and N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide derivatives. An exemplary compound of the present application is, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-l-methyl-2-oxo-l-azaspiro[4.5]dec-8-yl)-2H-indazole-5-carboxamide (Example 1): formula (VII).

To provide a compound to be used in treating Sjogren's syndrome.SOLUTION: A compound of the formula (I) or a pharmaceutically acceptable salt thereof is used.SELECTED DRAWING: None

Applicant discloses methods and uses of the heteroaryl ketone fused azadecalin compound relacorilant for treating patients suffering from endogenous hypercortisolism (CS) (including Cushing's syndrome and Cushing's Disease) effective reduce or prevent the loss of tissue lean mass; in embodiments, the methods and uses are effective to increase tissue lean mass as compared to the patient's tissue lean mass prior to administration of relacorilant. The methods and uses of relacorilant for treating patients suffering from CS are further effective to reduce body weight and waist circumference of the patient.Therapeutic amounts of relacorilant may be between about 50 milligrams per day (mg / day) and up to about 800 mg / day, e.g., 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, or 500 mg / day. The treatments may be oral treatments, and relacorilant may be administered with food, or without food. Relacorilant is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure:

Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver. Such liver disorders include fatty liver diseases are effective for reducing high levels of liver enzymes with a favorable safety profile. The methods and uses comprise administering to the subject an effective amount of a selective nonsteroidal glucocorticoid receptor modulator such as relacorilant, including methods and uses in combination with another drug, without adverse effects on liver enzyme levels, or on liver function. In embodiments, the other drug may be a drug that may cause liver toxicity, such as drugs that inhibit CYP3A enzymes, e.g., itraconazole or ketoconazole.

Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia: Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reeling or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.

The invention relates to a primary sicca syndrome noninvasive diagnosis system and device and a medium, and the system comprises an obtaining module which is used for obtaining salivary gland CT image data of a user; the diagnosis module is used for inputting the salivary gland CT image data of the user into a diagnosis model to obtain the prediction probability that the user suffers from the primary sicca syndrome; when the diagnosis model is constructed, on the basis of salivary gland CT image data of a plurality of patients, the parotid gland and the submandibular gland in the salivary gland CT image data of the patients are automatically segmented by adopting an automatic segmentation model to obtain gland regions; extracting radiological features from the gland region, and performing data enhancement on the extracted radiological features through a conditional variation auto-encoder to generate a balanced positive and negative sample data set; and based on the balanced positive and negative sample data sets, training a classification model by adopting an integrated learning strategy to obtain a diagnosis model, and analyzing the diagnosis model by utilizing an SHAP value analysis mode. According to the invention, the accuracy and precision of diagnosis can be improved.

The present invention relates to novel compounds useful as sensors for the rapid and specific determination of the FKBP12 protein, a peptidyl-prolyl cis-trans isomerase (PPlase), the levels of which in the biological fluids of a subject change if the subject is affected by pathological conditions, in particular neurodegenerative diseases, such as the Parkinson's disease and the Alzheimer's syndrome, tumour pathologies, autoimmune diseases, or if that subject is in a phase of acute rejection after organ transplantation.

This invention belongs to the field of biodetection technology, specifically relating to early warning biomarkers for Sjögren's syndrome and their applications. The biomarkers include plasma proteins selected from LGALS9, TNFRSF9, and CD5 proteins. The AUC value of this biomarker for early prediction of Sjögren's syndrome is 0.69.

The invention relates to the technical field of molecular biology, and provides a circular non-coding RNA (Ribonucleic Acid)-circRNA0049814 and application thereof. According to the invention, a molecular identification method based on circRNA0049814 expression detection in the PBMC is established, and a novel standard gene and an effective means are provided for early diagnosis of pSS. The implementation of the method is helpful for realizing early recognition of the primary sicca syndrome clinically through targeted screening, so that the risk of disease progression is expected to be reduced, and the prognosis of a patient is improved. Besides, functional experiments prove that circRNA0049814 has a regulating effect on proliferation of human submaxillary gland epithelial cells and the level of inflammatory factors in cell supernatant, the key role of circRNA0049814 in occurrence and development of the primary sicca syndrome is revealed, and the potential of circRNA0049814 in treatment of the primary sicca syndrome is proved.

The present invention relates to methods of using compounds of Formula I,wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

The application discloses a diagnostic marker for Sjogren's syndrome, a diagnostic device and application thereof, and relates to the technical field of Sjogren's syndrome diagnosis. The diagnostic marker for Sjogren's syndrome is selected from the markers in (1) or (2): (1) acetylcarnitine (C2); (2) C2, and at least one of the following markers: globulin concentration (G) in serum, ratio of free carnitine to acetylcarnitine (C0 / C2), decanoyl carnitine (C10), decatrienoyl carnitine (C10:3), propionyl carnitine / acetylcarnitine (C3 / C2), isovaleryl carnitine / butyryl carnitine (C5 / C4) and octanoyl carnitine / hexadecanoyl carnitine (C8 / C16). The diagnostic model constructed by single C2 has very high diagnostic efficiency for Sjogren's syndrome, and the combined use of multiple markers can further improve the diagnostic efficiency for Sjogren's syndrome.